{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:32:47Z","timestamp":1793046767693,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Taiwan University Hospital, Bei-Hu Branch"},{"name":"Ministry of Science and Technology, Taiwan","award":["MOST 106-2314-B-002-180-MY3 and MOST 109-2314-B-002-114-MY3"],"award-info":[{"award-number":["MOST 106-2314-B-002-180-MY3 and MOST 109-2314-B-002-114-MY3"]}]},{"name":"National Science and Technology, Taiwan","award":["NSTC 112-2314-B-002-134"],"award-info":[{"award-number":["NSTC 112-2314-B-002-134"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nutr J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cardiovascular disease (CVD) remains the foremost cause of mortality globally. Taurine, an amino acid, holds promise for cardiovascular health through mechanisms such as calcium regulation, blood pressure reduction, and antioxidant and anti-inflammatory effects. Despite these potential benefits, previous studies have yielded inconsistent results. This meta-analysis of randomized controlled trials (RCTs) aims to evaluate the existing evidence on the quantitative effects of taurine on hemodynamic parameters and cardiac function grading, which are indicative of overall cardiovascular health and performance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted an electronic search across multiple databases, including Embase, PubMed, Web of Science, Cochrane CENTRAL, and ClinicalTrials.gov, from their inception to January 2, 2024. Our analysis focused on key cardiovascular outcomes, such as heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular ejection fraction (LVEF), and New York Heart Association (NYHA)\u00a0Functional Classification. Meta-regression was applied to explore dose-dependent relationships based on the total taurine dose administered during the treatment period. A subgroup analysis, stratified according to the baseline disease status of patients, was also conducted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The analysis included a pooled sample of 808 participants from 20 randomized controlled trials. Taurine demonstrated a significant reduction in HR (weighted mean difference [WMD]\u2009=\u2009-3.579\u00a0bpm, 95% confidence interval [CI]\u2009=\u2009-6.044 to -1.114, <jats:italic>p<\/jats:italic>\u2009=\u20090.004), SBP (WMD\u2009=\u2009-3.999\u00a0mm Hg, 95% CI\u2009=\u2009-7.293 to -0.706, <jats:italic>p<\/jats:italic>\u2009=\u20090.017), DBP (WMD: -1.435\u00a0mm Hg, 95% CI: -2.484 to -0.386, <jats:italic>p<\/jats:italic>\u2009=\u20090.007), NYHA (WMD: -0.403, 95% CI: -0.522 to -0.283, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and a significant increase in LVEF (WMD: 4.981%, 95% CI: 1.556 to 8.407, <jats:italic>p<\/jats:italic>\u2009=\u20090.004). Meta-regression indicated a dose-dependent reduction in HR (coefficient\u2009=\u2009-0.0150 per g, <jats:italic>p<\/jats:italic>\u2009=\u20090.333), SBP (coefficient\u2009=\u2009-0.0239 per g, <jats:italic>p<\/jats:italic>\u2009=\u20090.113), DBP (coefficient\u2009=\u2009-0.0089 per g, <jats:italic>p<\/jats:italic>\u2009=\u20090.110), and NYHA (coefficient\u2009=\u2009-0.0016 per g, <jats:italic>p<\/jats:italic>\u2009=\u20090.111), and a positive correlation with LVEF (coefficient\u2009=\u20090.0285 per g, <jats:italic>p<\/jats:italic>\u2009=\u20090.308). No significant adverse effects were observed compared to controls. In subgroup analysis, taurine significantly improved HR in heart failure patients and healthy individuals. Taurine significantly reduced SBP in healthy individuals, heart failure patients, and those with other diseases, while significantly lowered DBP in hypertensive patients It notably increased LVEF in heart failure patients and improved NYHA functional class in both heart failure patients and those with other diseases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Taurine showed noteworthy effects in preventing hypertension and enhancing cardiac function. Individuals prone to CVDs may find it advantageous to include taurine in their daily regimen.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12937-024-00995-5","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T09:02:25Z","timestamp":1723712545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Insights into the cardiovascular benefits of taurine: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Chih-Chen","family":"Tzang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Huei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Vin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent","family":"\u00d6z\u00e7akar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"995_CR1","unstructured":"Cardiovascular diseases (CVDs) https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)"},{"key":"995_CR2","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","volume":"145","author":"CW Tsao","year":"2022","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP, Commodore-Mensah Y, et al. Heart Disease and Stroke Statistics-2022 Update: a report from the American Heart Association. Circulation. 2022;145:e153\u2013639.","journal-title":"Circulation"},{"key":"995_CR3","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney M-T, Corr\u00e0 U, Cosyns B, Deaton C, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315\u201381.","journal-title":"Eur Heart J"},{"key":"995_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1152\/physrev.1992.72.1.101","volume":"72","author":"RJ Huxtable","year":"1992","unstructured":"Huxtable RJ. Physiological actions of taurine. Physiol Rev. 1992;72:101\u201363.","journal-title":"Physiol Rev"},{"issue":"Suppl 1","key":"995_CR5","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/1423-0127-17-S1-S2","volume":"17","author":"SW Schaffer","year":"2010","unstructured":"Schaffer SW, Jong CJ, Ramila KC, Azuma J. Physiological roles of taurine in heart and muscle. J Biomed Sci. 2010;17(Suppl 1):S2.","journal-title":"J Biomed Sci"},{"key":"995_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41387-024-00289-z","volume":"14","author":"CC Tzang","year":"2024","unstructured":"Tzang CC, Chi LY, Lin LH, Lin TY, Chang KV, Wu WT, \u00d6z\u00e7akar L. Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials. Nutr Diabetes. 2024;14:29.","journal-title":"Nutr Diabetes"},{"key":"995_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/biomedicines12010144","volume":"12","author":"T-M Chang","year":"2024","unstructured":"Chang T-M, Lin H-L, Tzang C-C, Liang J-A, Hsu T-C, Tzang B-S. Unraveling the Role of miR-200b-3p in Attention-Deficit\/Hyperactivity Disorder (ADHD) and Its Therapeutic Potential in Spontaneously Hypertensive Rats (SHR). Biomedicines. 2024;12:144.","journal-title":"Biomedicines"},{"key":"995_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.4062\/biomolther.2017.251","volume":"26","author":"S Schaffer","year":"2018","unstructured":"Schaffer S, Kim HW. Effects and Mechanisms of Taurine as a Therapeutic Agent. Biomol Ther (Seoul). 2018;26:225\u201341.","journal-title":"Biomol Ther (Seoul)"},{"key":"995_CR9","unstructured":"Chapter 13: Assessing Risk of Bias Due to Missing Results in a Synthesis. https:\/\/training.cochrane.org\/handbook\/current\/chapter-13"},{"key":"995_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","volume":"22","author":"ML McHugh","year":"2012","unstructured":"McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22:276\u201382.","journal-title":"Biochem Med (Zagreb)"},{"key":"995_CR11","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"995_CR12","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. Version 6.2 https:\/\/training.cochrane.org\/handbook\/current\/chapter-10"},{"key":"995_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.","journal-title":"BMC Med Res Methodol"},{"key":"995_CR14","unstructured":"Chapter 6: Choosing Effect Measures and Computing Estimates of Effect https:\/\/training.cochrane.org\/handbook\/current\/chapter-06"},{"key":"995_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97\u2013111.","journal-title":"Res Synth Methods"},{"key":"995_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003;327:557\u201360.","journal-title":"Bmj"},{"key":"995_CR17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"key":"995_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/joacc.JOACC_36_20","volume":"11","author":"HV Zaki","year":"2021","unstructured":"Zaki HV, Sweed MS, Ali RM, Abdelhafeez MA. Taurine as an adjunct therapy for early left ventricular recovery in peripartum cardiomyopathy. J Obstet Anaesth Crit Care. 2021;11:9\u201314.","journal-title":"J Obstet Anaesth Crit Care"},{"key":"995_CR19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1161\/HYPERTENSIONAHA.115.06624","volume":"67","author":"Q Sun","year":"2016","unstructured":"Sun Q, Wang B, Li Y, Sun F, Li P, Xia W, Zhou X, Li Q, Wang X, Chen J, et al. Taurine supplementation lowers blood pressure and improves vascular function in prehypertension: randomized, double-blind, placebo-controlled study. Hypertension. 2016;67:541\u20139.","journal-title":"Hypertension"},{"key":"995_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/09537100400020575","volume":"16","author":"C Spohr","year":"2005","unstructured":"Spohr C, Br\u00f8ns C, Winther K, Dyerberg J, Vaag A. No effect of taurine on platelet aggregation in men with a predisposition to type 2 diabetes mellitus. Platelets. 2005;16:301\u20135.","journal-title":"Platelets"},{"key":"995_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/apt.14377","volume":"47","author":"R Schwarzer","year":"2018","unstructured":"Schwarzer R, Kivaranovic D, Mandorfer M, Paternostro R, Wolrab D, Heinisch B, Reiberger T, Ferlitsch M, Gerner C, Trauner M, et al. Randomised clinical study: the effects of oral taurine 6g\/day vs placebo on portal hypertension. Aliment Pharmacol Ther. 2018;47:86\u201394.","journal-title":"Aliment Pharmacol Ther"},{"key":"995_CR22","first-page":"62","volume":"50","author":"EM Sedova","year":"2010","unstructured":"Sedova EM, Magnitskaia OV. A clinical experience of taurine and trimetazidine use in premenopausal women with chronic heart failure. Kardiologiia. 2010;50:62\u20133.","journal-title":"Kardiologiia"},{"key":"995_CR23","first-page":"73","volume":"13","author":"VD Roshan","year":"2011","unstructured":"Roshan VD, Khalafi MK, Choobineh S. Effects of taurine supplementation on response of the cardiac injury biomarkers to bruce diagnostic protocol in patients with heart failure. Koomesh. 2011;13:73\u201382.","journal-title":"Koomesh"},{"key":"995_CR24","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1139\/apnm-2015-0560","volume":"41","author":"SG Ra","year":"2016","unstructured":"Ra SG, Choi Y, Akazawa N, Ohmori H, Maeda S. Taurine supplementation attenuates delayed increase in exercise-induced arterial stiffness. Appl Physiol Nutr Metab. 2016;41:618\u201323.","journal-title":"Appl Physiol Nutr Metab"},{"key":"995_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12986-022-00684-2","volume":"19","author":"J Moludi","year":"2022","unstructured":"Moludi J, Qaisar SA, Kadhim MM, Ahmadi Y, Davari M. Protective and therapeutic effectiveness of taurine supplementation plus low calorie diet on metabolic parameters and endothelial markers in patients with diabetes mellitus: a randomized, clinical trial. Nutr Metab (Lond). 2022;19:49.","journal-title":"Nutr Metab (Lond)"},{"key":"995_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/1479164110375971","volume":"7","author":"MA Moloney","year":"2010","unstructured":"Moloney MA, Casey RG, O\u2019Donnell DH, Fitzgerald P, Thompson C, Bouchier-Hayes DJ. Two weeks taurine supplementation reverses endothelial dysfunction in young male type 1 diabetics. Diab Vasc Dis Res. 2010;7:300\u201310.","journal-title":"Diab Vasc Dis Res"},{"key":"995_CR27","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1067\/mhj.2002.121927","volume":"143","author":"F Jeejeebhoy","year":"2002","unstructured":"Jeejeebhoy F, Keith M, Freeman M, Barr A, McCall M, Kurian R, Mazer D, Errett L. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J. 2002;143:1092\u2013100.","journal-title":"Am Heart J"},{"key":"995_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.15829\/1728-8800-2012-1-63-68","volume":"11","author":"IG Gordeev","year":"2012","unstructured":"Gordeev IG, Pokrovskaya EM, Luchinkina EE. Taurine effects on the occurrence of cardiac arrhythmias and QT interval dispersion in patients with post-infarction cardiosclerosis and chronic heart failure: a comparative randomised study. Cardiovasc Ther Prev. 2012;11:63\u20138.","journal-title":"Cardiovasc Ther Prev"},{"key":"995_CR29","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1161\/01.CIR.75.3.525","volume":"75","author":"T Fujita","year":"1987","unstructured":"Fujita T, Ando K, Noda H, Ito Y, Sato Y. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation. 1987;75:525\u201332.","journal-title":"Circulation"},{"key":"995_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jcjd.2020.05.004","volume":"45","author":"F Esmaeili","year":"2021","unstructured":"Esmaeili F, Maleki V, Kheirouri S, Alizadeh M. The effects of taurine supplementation on metabolic profiles, Pentosidine, soluble receptor of advanced glycation end products and methylglyoxal in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Can J Diabetes. 2021;45:39\u201346.","journal-title":"Can J Diabetes"},{"key":"995_CR31","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jjcc.2011.01.007","volume":"57","author":"MR Beyranvand","year":"2011","unstructured":"Beyranvand MR, Khalafi MK, Roshan VD, Choobineh S, Parsa SA, Piranfar MA. Effect of taurine supplementation on exercise capacity of patients with heart failure. J Cardiol. 2011;57:333\u20137.","journal-title":"J Cardiol"},{"key":"995_CR32","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/clc.4960080507","volume":"8","author":"J Azuma","year":"1985","unstructured":"Azuma J, Sawamura A, Awata N, Ohta H, Hamaguchi T, Harada H, Takihara K, Hasegawa H, Yamagami T, Ishiyama T, et al. Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial. Clin Cardiol. 1985;8:276\u201382.","journal-title":"Clin Cardiol"},{"key":"995_CR33","first-page":"543","volume":"34","author":"J Azuma","year":"1983","unstructured":"Azuma J, Sawamura A, Awata N, Hasegawa H, Ogura K, Harada H, Ohta H, Yamauchi K, Kishimoto S, Yamagami T, et al. Double-blind randomized crossover trial of taurine in congestive heart-failure. Curr Ther Res Clin Exp. 1983;34:543\u201357.","journal-title":"Curr Ther Res Clin Exp"},{"key":"995_CR34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1253\/jcj.56.95","volume":"56","author":"J Azuma","year":"1992","unstructured":"Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J. 1992;56:95\u20139.","journal-title":"Jpn Circ J"},{"key":"995_CR35","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/978-3-319-15126-7_51","volume":"803","author":"E Averin","year":"2015","unstructured":"Averin E. Use of taurine during rehabilitation after cardiac surgery. Adv Exp Med Biol. 2015;803:637\u201349.","journal-title":"Adv Exp Med Biol"},{"key":"995_CR36","unstructured":"Adamchik AS, Kryuchkova IV, Ruban GM, Blagodyreva YA. New potential of pharmaceutical therapy in diastolic chronic heart failure treatment. Russ J Cardiol. 2010;01(4):40\u20133."},{"key":"995_CR37","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1080\/19390211.2016.1267059","volume":"14","author":"M Ahmadian","year":"2017","unstructured":"Ahmadian M, Dabidi Roshan V, Ashourpore E. Taurine supplementation improves functional capacity, myocardial oxygen consumption, and electrical activity in heart failure. J Diet Suppl. 2017;14:422\u201332.","journal-title":"J Diet Suppl"},{"key":"995_CR38","doi-asserted-by":"publisher","first-page":"3s","DOI":"10.1016\/S0895-7061(99)00252-6","volume":"13","author":"WB Kannel","year":"2000","unstructured":"Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000;13:3s\u201310s.","journal-title":"Am J Hypertens"},{"key":"995_CR39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1161\/01.CIR.0000108928.25690.94","volume":"109","author":"RN Doughty","year":"2004","unstructured":"Doughty RN, Whalley GA, Walsh HA, Gamble GD, L\u00f3pez-Send\u00f3n J, Sharpe N. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation. 2004;109:201\u20136.","journal-title":"Circulation"},{"key":"995_CR40","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1123\/ijspp.2016-0570","volume":"12","author":"R Warnock","year":"2017","unstructured":"Warnock R, Jeffries O, Patterson S, Waldron M. The effects of caffeine, taurine, or caffeine-taurine Coingestion on repeat-sprint cycling performance and physiological responses. Int J Sports Physiol Perform. 2017;12:1341\u20137.","journal-title":"Int J Sports Physiol Perform"},{"key":"995_CR41","doi-asserted-by":"publisher","first-page":"e105851","DOI":"10.1371\/journal.pone.0105851","volume":"9","author":"AR Maia","year":"2014","unstructured":"Maia AR, Batista TM, Victorio JA, Clerici SP, Delbin MA, Carneiro EM, Davel AP. Taurine supplementation reduces blood pressure and prevents endothelial dysfunction and oxidative stress in post-weaning protein-restricted rats. PLoS One. 2014;9:e105851.","journal-title":"PLoS One"},{"key":"995_CR42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11906-018-0881-z","volume":"20","author":"M Waldron","year":"2018","unstructured":"Waldron M, Patterson SD, Tallent J, Jeffries O. The Effects of Oral Taurine on Resting Blood Pressure in Humans: a Meta-Analysis. Curr Hypertens Rep. 2018;20:81.","journal-title":"Curr Hypertens Rep"},{"key":"995_CR43","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1161\/HYPERTENSIONAHA.117.10546","volume":"71","author":"V Tsimihodimos","year":"2018","unstructured":"Tsimihodimos V, Gonzalez-Villalpando C, Meigs JB, Ferrannini E. Hypertension and Diabetes Mellitus. Hypertension. 2018;71:422\u20138.","journal-title":"Hypertension"},{"key":"995_CR44","doi-asserted-by":"crossref","unstructured":"Kim J-H. Chapter 11 - Heart and circulatory system. In J. Y. Cho (Ed.). Recent advancements in microbial diversity. London: Academic Press; 2022. p. 229\u2013254.","DOI":"10.1016\/B978-0-12-822368-0.00010-4"},{"key":"995_CR45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.12688\/wellcomeopenres.17505.2","volume":"7","author":"KA McGurk","year":"2022","unstructured":"McGurk KA, Kasapi M, Ware JS. Effect of taurine administration on symptoms, severity, or clinical outcome of dilated cardiomyopathy and heart failure in humans: a systematic review. Wellcome Open Res. 2022;7:9.","journal-title":"Wellcome Open Res"},{"key":"995_CR46","first-page":"85","volume":"21","author":"LS Mal'chikova","year":"1981","unstructured":"Mal\u2019chikova LS, Elizarova EP. Taurine and the adenosine cyclic monophosphate levels in the heart. Kardiologiia. 1981;21:85\u20139.","journal-title":"Kardiologiia"},{"key":"995_CR47","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1161\/01.CIR.0000124229.40424.80","volume":"109","author":"GY Oudit","year":"2004","unstructured":"Oudit GY, Trivieri MG, Khaper N, Husain T, Wilson GJ, Liu P, Sole MJ, Backx PH. Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload murine model. Circulation. 2004;109:1877\u201385.","journal-title":"Circulation"},{"key":"995_CR48","doi-asserted-by":"publisher","first-page":"C949","DOI":"10.1152\/ajpcell.00042.2004","volume":"287","author":"T Takatani","year":"2004","unstructured":"Takatani T, Takahashi K, Uozumi Y, Shikata E, Yamamoto Y, Ito T, Matsuda T, Schaffer SW, Fujio Y, Azuma J. Taurine inhibits apoptosis by preventing formation of the Apaf-1\/caspase-9 apoptosome. Am J Physiol Cell Physiol. 2004;287:C949\u201353.","journal-title":"Am J Physiol Cell Physiol"},{"key":"995_CR49","unstructured":"GRAS Exemption Claim for Taurine for Use in Enhanced Water Beverages https:\/\/www.fda.gov\/media\/93642\/download"},{"key":"995_CR50","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1152\/physrev.1968.48.2.424","volume":"48","author":"JG Jacobsen","year":"1968","unstructured":"Jacobsen JG, Smith LH. Biochemistry and physiology of taurine and taurine derivatives. Physiol Rev. 1968;48:424\u2013511.","journal-title":"Physiol Rev"},{"key":"995_CR51","doi-asserted-by":"publisher","first-page":"e13467","DOI":"10.14814\/phy2.13467","volume":"5","author":"CU Nielsen","year":"2017","unstructured":"Nielsen CU, Bjerg M, Ulaganathan N, Holm R. Oral and intravenous pharmacokinetics of taurine in sprague-dawley rats: the influence of dose and the possible involvement of the proton-coupled amino acid transporter, PAT1, in oral taurine absorption. Physiol Rep. 2017;5:e13467.","journal-title":"Physiol Rep"},{"key":"995_CR52","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/MEG.0000000000002297","volume":"34","author":"V Musazadeh","year":"2022","unstructured":"Musazadeh V, Dehghan P, Khoshbaten M. Efficacy of omega-3-rich Camelina sativa on the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, controlled trial. Eur J Gastroenterol Hepatol. 2022;34:537\u201345.","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Nutrition Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12937-024-00995-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12937-024-00995-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12937-024-00995-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T09:12:47Z","timestamp":1723713167000},"score":1,"resource":{"primary":{"URL":"https:\/\/nutritionj.biomedcentral.com\/articles\/10.1186\/s12937-024-00995-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["995"],"URL":"https:\/\/doi.org\/10.1186\/s12937-024-00995-5","relation":{},"ISSN":["1475-2891"],"issn-type":[{"value":"1475-2891","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]},"assertion":[{"value":"10 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}